High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.
Title | High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. |
Publication Type | Journal Article |
Year of Publication | 2011 |
Authors | Imam, M. H., Sinakos E., Gossard A. A., Kowdley K. V., Luketic V. A. C., M Harrison E., McCashland T., Befeler A. S., Harnois D., Jorgensen R., Petz J., Keach J., DeCook A. C., Enders F., & Lindor K. D. |
Journal | Aliment Pharmacol Ther |
Volume | 34 |
Issue | 10 |
Pagination | 1185-92 |
Date Published | 2011 Nov |
ISSN | 1365-2036 |
Keywords | Adult, Bilirubin, Cholagogues and Choleretics, Cholangitis, Sclerosing, Dose-Response Relationship, Drug, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Risk Factors, Time Factors, Treatment Outcome, Ursodeoxycholic Acid |
Abstract | BACKGROUND: Ursodeoxycholic acid (UDCA) in a dose of 28-30 mg/kg/day increases the likelihood of clinical deterioration of primary sclerosing cholangitis (PSC) patients. |
DOI | 10.1111/j.1365-2036.2011.04863.x |
Alternate Journal | Aliment Pharmacol Ther |
PubMed ID | 21957881 |
PubMed Central ID | PMC3752281 |
Grant List | R01 DK056924 / DK / NIDDK NIH HHS / United States DK 56924 / DK / NIDDK NIH HHS / United States |